 Trevi Therapeutics Inc NASDAQ: TRVI has announced positive results from its Phase 2b3 PRISM trial of Haduvio in treating prurigo nodularis, a chronic disease characterized by severe pruritus and the presence of nodules, lesions, and excoriations. In the trial, results. 